Benjamin Buck, PhD

Personal Statement

My research is focused on (1) developing innovative mHealth assessments and interventions for schizophrenia-spectrum disorders and cross-diagnostic persecutory ideation, as well as (2) “engagement mHealth,” or the development of mobile health interventions that increase the likelihood that underserved populations present to and receive evidence-based treatment, with a particular focus on young adults at risk for psychosis and their families. My research is supported by a NARSAD Young Investigator Award from the Brain and Behavior Research Foundation and multiple grants from NIMH including a K23 Mentored Patient-Oriented Research Career Development Award. Prior to my faculty position at UW, I was an Advanced Fellow in VA Health Services Research and Development and the Department of Health Services at UW. I completed my clinical psychology internship at the VA Puget Sound Health Care System, where I was awarded the APA Division 18 Outstanding VA Trainee Award. Prior to internship, I completed my undergraduate and doctoral training at the University of North Carolina at Chapel Hill. Throughout my training, I have been dedicated to services for individual with serious mental illness, with experience in an inpatient state hospital, VA psychosocial rehabilitation, intensive outpatient and dual-diagnosis clinics, and in coordinated specialty care for young people with early psychosis. In addition to my program of research and clinical work, I am committed to clinical supervision and training. I currently lead the development of one of the first clinical training sequences designed for frontline clinicians integrating mHealth into community mental health. I was the first-ever graduate student to win UNC’s David Galinsky Award, an honor recognizing excellence in clinical supervision that had previously only ever been won by faculty. I am currently active in providing supervision in CBT to third-year psychiatry residents at UW.

Department Affiliations

Recent Publications

A preliminary study examining terminology used by individuals with lived experience describing beliefs about being targeted or harmed by others.
(2023 May)
Psychiatry Res 323(): 115129
Buck B, Wingerson M, Chander A, Tauscher JS

Cardiovascular Magnetic Resonance Imaging in Patients With Ibrutinib-Associated Cardiotoxicity.
(2023 Apr 1)
JAMA Oncol 9(4): 552-555
Buck B, Chum AP, Patel M, Carter R, Nawaz H, Yildiz V, Ruz P, Wiczer T, Rogers KA, Awan FT, Bhat S, Guha A, Kittai AS, Simonetti OP, Raman SV, Wallace G, Sanchez R, Bonsu JM, Gambril J, Haddad D, Mann J, Wei L, Kola-Kehinde O, Byrd JC, Woyach JA, Addison D

The relationship between appraisals of auditory verbal hallucinations and real-time affect and social functioning.
(2022 Dec)
Schizophr Res 250(): 112-119
Buck B, Munson J, Chander A, Wang W, Brenner CJ, Campbell AT, Ben-Zeev D

Carfilzomib-induced Cardiotoxicity: An Analysis of the FDA Adverse Event Reporting System (FAERS).
J Saudi Heart Assoc 34(3): 134-141
Buck B, Kellett E, Addison D, Vallakati A

Developing the Workforce of the Digital Future: Leveraging Technology to Train Community-Based Mobile Mental Health Specialists.
(2022 Aug 3)
J Technol Behav Sci
Buck B, Kopelovich SL, Tauscher JS, Chwastiak L, Ben-Zeev D

Show complete publication list »
Edit Profile